Pivotal SPRAY-CB Trial of RejuvenAir® Published in American Journal of Respiratory and Critical Care Medicine
Why now
Thesis: Positive pivotal data supports device approval prospects
Catalyst to watch: Regulatory submission or FDA decision
Main risk: Private company; approval and reimbursement uncertain
Why it matters
Published pivotal trial data showing reduced severe exacerbations supports potential regulatory and commercial path.
Details
Randomized, blinded, sham-controlled pivotal trial demonstrates clinically meaningful improvements in quality of life and COPD symptoms, with a 38.4% relative reduction in severe exacerbation rates BOSTON, Sept. 23, 2026 /PRNewswire/ -- CSA Medical, Inc., a medical device company focused...
Related assets & topics
HealthcareSources
- prnewswire · 2026-09-23 11:00 UTC